ClinicalTrials.gg
Active, not recruitingNCT03707938Updated Nov 10, 2026

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

A Phase 1 interventional study of Brigatinib and Local Consolidation Therapy in Advanced Lung Carcinoma, ALK Gene Rearrangement and Lung Non-Small Cell Carcinoma, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing brigatinib in Carcinoma, Non-Small-Cell Lung — none open to participants now, 4 under way, none of them phase 3. brigatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 12
35 · median 33
Started
2018
the only one that year
Phase 1
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
2 of 12
M.D. Anderson Cancer Center

Among the 12 studies testing brigatinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 1, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 12 studies testing brigatinib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About brigatinib

brigatinib: first FDA approval 2017 (ALUNBRIG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing brigatinib in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This early phase I trial studies the side effects and how well local consolidative therapy (LCT) and brigatinib works in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Giving LCT, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LCT and brigatinib may work better in treating patients with non-small cell lung cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the safety, tolerability, and feasibility of brigatinib with local consolidative therapy (LCT) in tyrosine kinase inhibitor-naive ALK-rearranged advanced (non-small cell lung cancer) NSCLC.

SECONDARY OBJECTIVES:

I. To determine progression-free survival (PFS) using modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in advanced ALK+ NSCLC patients treated with local consolidative therapy (LCT) after achieving stable disease or partial response with first-line brigatinib treatment.

II. To determine overall survival (OS).

III. To assess time to progression (TTP) of non-LCT lesions.

EXPLORATORY OBJECTIVES:

I. To assess time to appearance of new metastatic lesion(s).

II. To determine the utility of pre-treatment, pre-LCT, and post-LCT circulating free tumor deoxyribonucleic acid (DNA) (cfDNA) as a potential prognostic and predictive biomarkers.

II. To evaluate potential impact of LCT on mechanisms of ALK resistance with molecular analysis of post-progression biopsies.

OUTLINE:

Patients receive brigatinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and every 3 months for up to 2 years.

03

Conditions studied

  • Advanced Lung Carcinoma
  • ALK Gene Rearrangement
  • Lung Non-Small Cell Carcinoma
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)
  2. Documented ALK re-arrangement as detected by: (1) FISH, (2) IHC, (3) tissue NGS, or (4) cfDNA NGS
  3. Subjects can be enrolled as (1) TKI naïve or (2) after ≤ 8 weeks of brigatinib treatment without disease progression.
  4. Candidate for local consolidative therapy to at least one site of residual disease
  5. (ECOG) performance status of 0 to 2
  6. Males or females aged at least 18 years.
  7. Adequate organ function laboratory values, defined as:

    1. (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L
    2. count at least 75,000/mm3 or at least 75 x 109/L
    3. (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline
    4. Serum creatinine ≤ 1.5 × or ≥ 60 mL/minute for subjects with creatinine levels > 1.5 × the institutional ULN
    5. Serum total less than or equal to ≤ 1.5 × ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 × ULN
    6. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN except for subjects with liver mets for whom ALT and AST should be ≤ 5× ULN
    7. (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
    8. Activated PTT (aPTT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant
  8. Female patients of must have a negative pregnancy test documented at time of screening.
  9. Female patients who:

    1. Are for at least 1 year before the screening visit, OR
    2. Are surgically sterile, OR
    3. If they are of childbearing potential, agree to use a highly effective method of from the time of signing the through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
  10. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:

    1. Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
    2. Agree to completely abstain from heterosexual intercourse
  11. Have normal on screening evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.
  12. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have been diagnosed with another primary other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non- prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy.
  2. Previously received any prior TKI, including ALK-targeted TKIs. Note: on-going brigatinib use as specified in the Inclusion criteria is allowed.
  3. Previously received more than 1 regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease. Note that history of consolidative immunotherapy after concurrent chemoradiotherapy (for locally advanced disease) is allowed.
  4. Symptomatic . Asymptomatic CNS disease requiring increasing dose of within 7 days prior to study enrollment is also not permitted.
  5. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with and without cord compression are allowed.
  6. The presence of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis at screening.
  7. Have a known or suspected to brigatinib or its .
  8. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug.
  9. Be pregnant, planning a pregnancy, or breastfeeding.
  10. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    1. Myocardial infarction (MI) within 6 months prior to the first dose of study drug
    2. Unstable angina within 6 months prior to first dose of study drug
    3. Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug
    4. History of atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician
    5. Any history of ventricular arrhythmia
    6. Cerebrovascular accident or within 6 months prior to first dose of study drug
  11. Have uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure
  12. Have an ongoing or active infection, including, but not limited to, the requirement for intravenous (IV) antibiotics.
  13. Have a known history of (HIV) infection. Testing is not required in the absence of history.
  14. Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the study drug.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Treatment (brigatinib, LCT)

    Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Brigatinib · Procedure: Local Consolidation Therapy

Interventions

  • Given PO

    Also known as: Alunbrig, AP 26113, AP-26113, AP26113

  • ProcedureLocal Consolidation Therapy

    Undergo local consolidative therapy

    Also known as: LCT, Local Consolidative Therapy

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Toxicity data will be summarized using frequency tables. Associations between the types and severity of toxicity and treatment will be evaluated as well.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-free survival (PFS)

    The median PFS will be calculated and presented with 2-sided 80% confidence interval (CI). Kaplan-Meier survival probabilities will be plotted over time.

    Time frame: From the date of brigatinib treatment initiation until disease progression or death, assessed up to 2 years

  2. Overall survival (OS)

    The median OS will be calculated and presented with 2-sided 80% CI. Kaplan-Meier survival probabilities will be plotted over time.

    Time frame: From the date of brigatinib treatment initiation until date of death from any cause, assessed up to 2 years

  3. Time to progression of non-local consolidative therapy (LCT) lesion

    The median time to progression of non-LCT lesion will be calculated and presented with 2-sided 80% CI. Kaplan-Meier survival probabilities will be plotted over time.

    Time frame: From the date of brigatinib treatment initiation until progression of a baseline lesion not treated with radiation or surgery, assessed up to 2 years

Other outcomes

  1. Time to appearance of new metastatic lesion(s) (TANM)

    Descriptive statistics (e.g. median, standard deviations, range) will be used to quantify TANM.

    Time frame: From the date of brigatinib treatment initiation until development of a new lesion, assessed up to 2 years

  2. Potential prognostic and predictive biomarkers

    Multi-covariate and multivariate analysis tools such as the logistic regression, generalized linear model, classification and regression tree, canonical correlation, correspondence analysis, etc., will be applied to study the association among various immunological markers, genomic markers, treatments, and the toxicity and efficacy outcomes.

    Time frame: Up to 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Jan 2028, 109 months after the start.

Of 225 non-industry phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 109 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2026 → Jan 2028 and completion Jan 2026 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2018
First posted
Oct 16, 2018
StartActual
Dec 18, 2018
Primary completionEst.
Jan 28, 2028was Jan 2026
CompletionEst.
Jan 28, 2028was Jan 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 28, 2026→Jan 28, 2028
Nov 10, 2026
Study completion
Jan 28, 2026→Jan 28, 2028
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jan 28, 2026→Jan 28, 2028
    Study completion Jan 28, 2026→Jan 28, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03707938
Responsible party
Sponsor
First posted
Oct 16, 2018
Start date
Dec 18, 2018
Primary completion
Jan 28, 2028 (estimated)
Completion
Jan 28, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Yasir Y Elamin, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brigatinib

Start the discussion